Spotlight on the perioperative use of maropitant citrate

Bonnie L Hay Kraus Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA Abstract: Neurokinin-1 (NK-1) receptors are present in both the central nervous system and peripheral tissues. Substance P (SP) is the major ligand and is involved in mu...

Full description

Bibliographic Details
Main Author: Hay Kraus BL
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:Veterinary Medicine : Research and Reports
Subjects:
Online Access:https://www.dovepress.com/spotlight-on-the-perioperative-use-of-maropitant-citrate-peer-reviewed-article-VMRR
id doaj-58ef5dff6e5848a3841113323937bb50
record_format Article
spelling doaj-58ef5dff6e5848a3841113323937bb502020-11-24T23:24:31ZengDove Medical PressVeterinary Medicine : Research and Reports2230-20342017-08-01Volume 8415134404Spotlight on the perioperative use of maropitant citrateHay Kraus BLBonnie L Hay Kraus Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA Abstract: Neurokinin-1 (NK-1) receptors are present in both the central nervous system and peripheral tissues. Substance P (SP) is the major ligand and is involved in multiple processes including pain transmission, vasodilation, modulation of the inflammatory response, as well as the sensory neuronal transmission involved in stress, anxiety, and emesis. The involvement of NK-1 and SP in the vomiting reflex has led to the development of NK-1 antagonists to prevent and treat vomiting in human and veterinary medicine. Maropitant is a potent, selective neurokinin (NK-1) receptor antagonist that blocks the pharmacologic action of SP in the central nervous system. Maropitant is available in both an injectable and tablet formulation and approved for use in dogs and cats for the treatment and prevention of vomiting from a variety of clinical causes and motion sickness. When administered prior to anesthetic premedication, maropitant prevents or significantly decreases the incidence of opioid-induced vomiting and signs of nausea in dogs and cats. Maropitant has also been shown to improve postoperative return to feeding and food intake in dogs. The minimum alveolar concentration of sevoflurage is decreased in both dogs and cats by maropitant, indicating a potential role as an adjunct analgesic, especially for visceral pain. This article will review the background information and literature, including clinical recommendations with respect to the perioperative use of maropitant in canine and feline veterinary patients. Keywords: maropitant, perioperative nausea and vomiting, neurokinin-1 antagonist, Substance Phttps://www.dovepress.com/spotlight-on-the-perioperative-use-of-maropitant-citrate-peer-reviewed-article-VMRRmaropitantperi-operative nausea and vomitingneurokinin-1 antagonistsubstance P
collection DOAJ
language English
format Article
sources DOAJ
author Hay Kraus BL
spellingShingle Hay Kraus BL
Spotlight on the perioperative use of maropitant citrate
Veterinary Medicine : Research and Reports
maropitant
peri-operative nausea and vomiting
neurokinin-1 antagonist
substance P
author_facet Hay Kraus BL
author_sort Hay Kraus BL
title Spotlight on the perioperative use of maropitant citrate
title_short Spotlight on the perioperative use of maropitant citrate
title_full Spotlight on the perioperative use of maropitant citrate
title_fullStr Spotlight on the perioperative use of maropitant citrate
title_full_unstemmed Spotlight on the perioperative use of maropitant citrate
title_sort spotlight on the perioperative use of maropitant citrate
publisher Dove Medical Press
series Veterinary Medicine : Research and Reports
issn 2230-2034
publishDate 2017-08-01
description Bonnie L Hay Kraus Department of Veterinary Clinical Sciences, Iowa State University College of Veterinary Medicine, Ames, IA, USA Abstract: Neurokinin-1 (NK-1) receptors are present in both the central nervous system and peripheral tissues. Substance P (SP) is the major ligand and is involved in multiple processes including pain transmission, vasodilation, modulation of the inflammatory response, as well as the sensory neuronal transmission involved in stress, anxiety, and emesis. The involvement of NK-1 and SP in the vomiting reflex has led to the development of NK-1 antagonists to prevent and treat vomiting in human and veterinary medicine. Maropitant is a potent, selective neurokinin (NK-1) receptor antagonist that blocks the pharmacologic action of SP in the central nervous system. Maropitant is available in both an injectable and tablet formulation and approved for use in dogs and cats for the treatment and prevention of vomiting from a variety of clinical causes and motion sickness. When administered prior to anesthetic premedication, maropitant prevents or significantly decreases the incidence of opioid-induced vomiting and signs of nausea in dogs and cats. Maropitant has also been shown to improve postoperative return to feeding and food intake in dogs. The minimum alveolar concentration of sevoflurage is decreased in both dogs and cats by maropitant, indicating a potential role as an adjunct analgesic, especially for visceral pain. This article will review the background information and literature, including clinical recommendations with respect to the perioperative use of maropitant in canine and feline veterinary patients. Keywords: maropitant, perioperative nausea and vomiting, neurokinin-1 antagonist, Substance P
topic maropitant
peri-operative nausea and vomiting
neurokinin-1 antagonist
substance P
url https://www.dovepress.com/spotlight-on-the-perioperative-use-of-maropitant-citrate-peer-reviewed-article-VMRR
work_keys_str_mv AT haykrausbl spotlightontheperioperativeuseofmaropitantcitrate
_version_ 1725560360615804928